Edavit 1.5mg Injection

Introduction

Edavit is a prescription medication that contains the active ingredient Edaravone. It is available in injectable form and is commonly used in the treatment of certain conditions.

Uses

Edavit is primarily prescribed for the management of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. ALS is a progressive neurodegenerative disease that affects the nerve cells responsible for controlling voluntary muscles. Edavit can help slow down the progression of the disease and improve the patient’s functional abilities.

Dosage and Administration

The dosage of Edavit may vary depending on the individual patient’s condition and response to treatment. It is typically administered under the supervision of a healthcare professional in a hospital or clinical setting. The injection is given intravenously, directly into a vein.

Mechanism of Action

Edaravone, the active ingredient in Edavit, is a potent antioxidant that works by reducing oxidative stress in the body. Oxidative stress is known to contribute to the progression of ALS. By reducing oxidative stress, Edavit helps protect nerve cells from damage and slows down the degenerative process.

Side Effects

Common side effects may include headache, dizziness, and bruising at the injection site. These side effects are generally mild and temporary. However, if any of these side effects persist or worsen, notify your healthcare provider.

In rare cases, Edavit may cause more serious side effects. These can include difficulty breathing, chest pain, or signs of an allergic reaction such as rash, itching, or swelling. If any of these serious side effects occur, seek immediate medical attention.

Drug Interactions

inform your healthcare provider about all the medications you are currently taking, including prescription drugs, over-the-counter medications, and herbal supplements. Edavit may interact with certain medications, potentially affecting their efficacy or increasing the risk of side effects. Common drug interactions may include certain anticoagulants (blood thinners) and medications that affect liver function. Your healthcare provider will carefully evaluate the potential risks and benefits before prescribing Edavit.

Precautions

Before starting treatment with Edavit, inform your healthcare provider about any existing medical conditions, especially if you have a history of liver or kidney disease. Edavit should be used with caution in these patients.

Additionally, avoid certain substances while taking Edavit. Alcohol and certain medications, such as sedatives or tranquilizers, may enhance the sedative effects of Edavit. Discuss with your healthcare provider any questions or concerns regarding potential interactions.

Storage

Patient Tips

• Follow the dosage instructions provided by your healthcare provider carefully.
• Keep all follow-up appointments with your healthcare provider to monitor your response to treatment.
• Report any unusual side effects or changes in your condition to your healthcare provider.
• Do not stop taking Edavit without consulting your healthcare provider first.
• Keep a record of the medication’s administration dates and any side effects experienced.
• Store the medication in a safe and secure place, away from direct sunlight and moisture.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Edaravone oral/injection (Drugs.com) [Accessed 16 Jun. 2024] (online) Available at:
• edaravone 105 mg/5 ml oral suspension (RX) [Accessed 15 Jun. 2024] (online) Available at:
• Edaravone Oral (MedlinePlus) [Accessed 28 Jun. 2024] (online) Available at:
• Dang R, Wang M, Li X, Wang H, Liu L, Wu Q, Zhao J, Ji P, Zhong L, Licinio J, Xie P. Edaravone ameliorates depressive and anxiety-like behaviors via Sirt1/Nrf2/HO-1/Gpx4 pathway. J Neuroinflammation. 2022 Feb 7;19(1):41. doi: 10.1186/s12974-022-02400-6. [Accessed 22 Jun. 2024] Available at: